#USA #FDA Approval #Los Gatos #Supira Medical #pVAD

Supira Medical Achieves FDA Approval for SUPPORT II Trial

Supira Medical, Inc., a clinical-stage organization that is innovating the percutaneous ventricular assist device (pVAD) sector, has officially announced the FDA's endorsement of their SUPPORT II pivotal trial. This critical development is set to facilitate the submission of a premarket approval (PMA) application, signaling an essential step towards market availability in the U.S. for their groundbreaking product.

The SUPPORT II trial, or the SUpira System in Patients Undergoing High-Risk Percutaneous COronaRy InTervention (HRPCI), is designed as a randomized controlled study. Its primary focus is to evaluate both the safety and efficacy of the next-generation pVAD, specifically in patients undergoing high-risk coronary interventions. With plans to enroll up to 385 patients across a maximum of 40 U.S. sites, this study will be spearheaded by esteemed co-principal investigators, Dr. Ajay Kirtane from Columbia University and Dr. David Kandzari from the Piedmont Heart Institute.

Dr. Kandzari emphasized the significance of effective hemodynamic support during HRPCI procedures, noting that it hinges on various factors, including accessibility and operational efficiency. The introduction of a smaller, more efficient system could greatly expand treatment options for a broader patient demographic.

Additionally, Dr. Kirtane highlighted the potential of the pVAD to enhance the safety and effectiveness of complex procedures, providing patients who may otherwise be limited in options with crucial medical care.

Advances in Cardiogenic Shock Management

In conjunction with the SUPPORT II trial, Supira Medical is actively seeking to enhance treatment solutions for patients experiencing cardiogenic shock—a severe condition characterized by the heart's inability to effectively pump blood, often following heart attacks or heart failure. Early case experiences in international markets involve utilizing a percutaneous axillary access approach, allowing for improved patient mobility while an active 10Fr pVAD is in use. This innovative advancement signifies a shift in the management of critically ill patients, paving the way for better outcomes and wider access to treatment.

These developments are poised to redefine standards in temporary mechanical circulatory support, with a focus on mobility and extended options for intervention among both cardiologists and heart failure specialists.

D. Keith Grossman's Appointment to the Board

In alignment with these pivotal advancements, Supira has welcomed D. Keith Grossman to its Board of Directors. With over 40 years of experience in the medical technology realm and a foundational role in mechanical circulatory support, Grossman’s expertise is invaluable as the company gears up for market readiness and growth.

Dr. Nitin Salunke, Supira's President and CEO, commented on Grossman's appointment, citing the combination of operational discipline and strategic insight he brings to the team. As Grossman affirms, Supira is well-positioned in the evolving pVAD landscape, and he is keen to lend his support to advance the company’s pivotal trials and subsequently, its presence in critical care treatment avenues.

About Supira Medical, Inc.

Focused on creating advanced pVAD solutions for high-risk patients undergoing interventional procedures, Supira Medical's innovations aim to enhance the quality of care in cardiology. Their system has already aided 99 patients, showcasing its potential as a leading solution in the evolving pVAD market. Currently, the Supira System remains investigational and is not yet approved for marketing in the U.S. or globally. For more detailed information about Supira Medical, visit their official website at www.supiramedical.com.

In summary, Supira Medical stands at the forefront of potentially revolutionary advancements in heart care technology, as it embarks on the SUPPORT II trial aimed at improving outcomes for patients facing critical cardiac challenges.